Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI | NASDAQ:IMUX
Emily Jarvie, a journalist with experience in political, business, and scientific reporting, joined Proactive in 2022. Proactive provides global investment news, operating in finance hubs worldwide, focusing on medium and small-cap markets, blue-chip companies, and emerging technologies. The company uses technology to enhance workflows but maintains human authorship for all content.
Reference News
Emily Jarvie, a journalist with experience in political, business, and scientific reporting, joined Proactive in 2022. Proactive provides global investment news, operating in finance hubs worldwide, focusing on medium and small-cap markets, blue-chip companies, and emerging technologies. The company uses technology to enhance workflows but maintains human authorship for all content.